Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,085 full-time employees. The company went IPO on 2019-05-09. The firm has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The firm conducts business primarily in the United States, China, Europe and other regions.
How did VBIZF's recent EPS compare to expectations?
The most recent EPS for VIVA Biotech Holdings is $, expectations of $.
How did VIVA Biotech Holdings VBIZF's revenue perform in the last quarter?
VIVA Biotech Holdings revenue for the last quarter is $
What is the revenue estimate for VIVA Biotech Holdings?
According to of Wall street analyst, the revenue estimate of VIVA Biotech Holdings range from $ to $
What's the earning quality score for VIVA Biotech Holdings?
VIVA Biotech Holdings has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does VIVA Biotech Holdings report earnings?
VIVA Biotech Holdings next earnings report is expected in 2025-06-25
What are VIVA Biotech Holdings's expected earnings?
VIVA Biotech Holdings expected earnings is $, according to wall-street analysts.
Did VIVA Biotech Holdings beat earnings expectations?
VIVA Biotech Holdings recent earnings of $ expectations.